The Standard for the Exchange of Nonclinical Data (SEND) is an implementation of the Study Data Tabulation Model for nonclinical studies that enables the U.S. Food and Drug Administration (FDA) to modernize and streamline the review process. As a result, patients may benefit from speedier approval of new drugs. However, SEND implementation and compliance can be challenging and require effective cooperation between pharmaceutical companies and contract research organizations. In order to improve Society of Toxicologic Pathology (STP) members' awareness about SEND, including the steps, obstacles, and mistakes to avoid in its implementation while applying for FDA approval, the Career Development and Outreach Committee of the STP sponsored a career development lunchtime series panel discussion entitled "The Standard for the Exchange of Nonclinical Data (SEND): Challenges and Promise" in conjunction with the STP 37th Annual Symposium. The presentations and discussion at this workshop provided perspectives of experts including pathologists and information technology professionals familiar with the SEND submission process and FDA reviewers. This article is designed to provide brief summaries of their talks as well as the questions asked during this well-received panel discussion. The SEND Implementation Guide (SENDIG) 3.0 currently supports single-dose general toxicity, repeat-dose general toxicity, and carcinogenicity studies for NDA/ANDA, BLA, and IND submissions. Safety pharmacology and reproductive toxicology are out of scope for SEND 3.0 but will be supported in future versions of SEND. Recently published SENDIG 3.1 contains a subset of safety pharmacology, including respiratory and cardiovascular studies (Standard for Exchange 2016). The SEND Developmental and Reproductive Toxicology
Implementation Guide (DARTIG) 1.0 for embryo fetal development has also been recently published. DARTIG 1.0 is not yet required but has been released to allow development and validation of tools ahead of implementation (Standard for Exchange 2016). The main promise of SEND is to reduce the NDA examination time by enabling the FDA to receive, process, review, and archive submissions more efficiently and effectively. SEND implementation and compliance, however, can be challenging and require effective cooperation between pharmaceutical companies and contract research organizations (CROs). Continuously evolving SEND standards present challenges to the industry, including data management and information technology (IT) support, quality assurance (QA), and integration of data from multiple test sites.
The 
SEND: Challenges and Promises in a Big CRO
Audrey Walker (CRL) presented an overview on challenges, prospects, and promises of implementing SEND in a big CRO like CRL. Audrey has been in the IT industry for over 25 years and has worked with preclinical data for over 20 years. She led the validation and implementation of SEND data for submission compliance for CRL and continues to lead the team today. Audrey also provides guidance to sponsors and labs trying to implement SEND. In 2007, Audrey joined the CDISC SEND team as a coauthor of the CDISC SEND Implementation Guides 3.0 and 3.1 and is also a member of the CDISC Global 
Challenges
Challenges that CRL encountered were many and the complexity was magnified due to our global footprint. We quickly realized that harmonization across our sites would be key in order to be successful, and so we began the journey of reviewing terminology and processes in order to align with CDISC as closely as possible. This was a process that took many years to accomplish and we continue to harmonize where possible as the process evolves.
The effort to review and update data collection processes to align with CDISC SEND was very labor intensive and disruptive to daily operations. CRL reviewed practices from the animal arrival, to in-life, through to necropsy and histopathology data collection. Although everyone acknowledged the importance of the effort, the amount of changes needed in order to streamline the process were many and the learning curve was steep. Training and informational sessions were held with staff continuously throughout the implementation to communicate what SEND was and why these changes were occurring. Charles River now collects more data online than we ever have before! Another challenging task that was essential to the completion of our compliance journey was the mapping of Charles River terminology to CDISC SEND terminology. Through many collaborative sessions between the SEND team and our scientists, we mapped over 10,000 terms for our original go live and continue to update these mappings as terminology is updated.
As we became closer to completing the validation of our system, we began to pilot with a number of sponsors. This exercise was crucial in solidifying our internal processes for SEND creation and also clarifying how we would transfer this new deliverable to our sponsors. A new challenge became evident as we worked through different scenarios. Multisite studies! How were we going to handle data being provided by test sites outside of CRL? It quickly became evident that SEND knowledge and capabilities differed greatly across the industry. Through collaborative sessions with all parties involved, we have defined our process and frequently educate our sponsors and other interested parties on our best practice.
Should QA be involved with SEND data sets or not, was a big debate internally as well as externally. This debate continues today. Whether SEND should be included in the protocols is another debate that continues within industry. A possible future state may be that the FDA will become accustomed to the SEND data sets and eventually announce they no longer need the individual animal listings and that the SEND data sets will replace them. At this point, the SEND data sets would become subject to QA audit and study director review and, therefore, be included as standard within the protocols/study plans. [Note: This is the opinion of Audrey Walker's and not that of CRL.] SEND will continue to change and improve as the industry uses the model and submits data to the FDA. Issues are starting to come to light that point to areas that need further clarification and the CDISC team is updating the implementation guides accordingly. SEND is new to all including the FDA, so there will be updates and further clarifications as we continue this journey. We are all learning, and are all in it together, so we all need to work together as partners to make this important initiative succeed.
Prospects and Promises
With SEND data sets, both sponsors and the FDA can review the data more efficiently and effectively. Once you start to review data electronically, you will not want to go back to paper PDF review. It is only a matter of time before everyone will have visualization tools to review the data and will have forgotten what it was like to review data in PDF paper form.
[Note: This is the opinion of Audrey Walker.]
Many sponsors are creating data warehouses to mine their SEND data. As this format becomes easier to produce the expectation of receiving SEND data sets before the finalization of the study will become the norm. With the data in a warehouse, you can mine across a compound, across species, compound class; the sky is the limit.
The benefit Charles River has seen from SEND has been the urgency it created for us to harmonize processes and glossaries across the safety assessment unit. Due to the numerous process changes made, we encounter fewer data issues than we did before the inception of SEND. Moving forward, Charles River will continue to change processes as new guidance documents are released. We will continue to evaluate the collection of data electronically. We will continue to train staff both technical and scientific about new SEND initiatives as they are released. We look forward to the new era of electronic SEND data.
SEND: Challenges and Promises in a Small CRO
Dr. Kathleen Funk (EPL) provided an overview on challenges, prospects, and promises of implementing SEND in a small CRO like EPL. Dr. Funk, is a board certified pathologist and President of EPL, Inc., a CRO that handles preclinical histopathology, primary and peer review evaluations, and consultations for a wide variety of companies and institutions. EPL does not have an in-life facility; consequently SEND issues that directly concern in-life data are not encountered. However, EPL generates SEND data that must be incorporated into the larger SEND files generated from in-life studies, and this is accomplished by working closely with other preclinical CROs.
As it relates to SEND, Dr. Funk's responsibilities include managerial and business decisions that involve the deployment of resources, while SEND package generation is accomplished by EPL IT personnel and trained technicians.
Challenges
Challenges and obstacles overcome in implementing SEND at EPL are three-fold and classified as technical, internal, and client-related issues. The technical considerations are that the SEND software is still nascent and we had to overcome some implementation obstacles. Furthermore, the SEND software is evolving rapidly, resulting in more frequent software updates, each requiring new validation efforts.
Internal issues include the disruption to the flow of our internal business processes and the fact that we had to develop standard operating procedures and decide when we would create the SEND files in the reporting process. While IT was necessarily involved in SEND implementation, we also had to create a new position and decide the personnel who would best fit this position's job requirements. We discussed what the role of quality control (QC) and QA would be and decided that there is no role for QA since we would generate the SEND files after the final audit of the tables and narrative. It was decided that QC would review the Study Data Reviewers Guide (SDRG) and validation report. QA would not be involved at all since the SEND data are put together after their review is complete. This decision appears to be the consensus of the QA industry. We acknowledge that training will be ongoing as the standards evolve and validation activities will be more frequent as the standards evolve. Another internal issue is that it still is difficult to predict how much time a given study will take to generate an error-free SEND report.
Client-related issues include the fact that some clients are unfamiliar with SEND and sometimes don't know whether they need SEND files. Additionally, since we are a histopathology CRO with no in-life component, not all aspects of the SDRG apply to EPL. We have decided to be proactive and inquire before a study is undertaken whether SEND files will be required and what domains do the client want us to generate. The bulk of our work focuses on the following domains: demographics (which contains animal information), microscopic findings (MI), macroscopic findings, and related records (RELREC, which is where correlated findings are identified). We have found we need to suggest the domains as RELREC, dealing with microscopic correlations, as this has often been overlooked by clients as a SEND file they would like to have generated. We also have requests for SEND files from older studies that were input into a non-SEND pathology data capture system. This request particularly segues into the question of how much to bill for SEND files. Another client-related issue is getting the proper information from our client. For example, USUBJID, which is the unique subject identifier for an animal, requires a specific naming convention, which we do not always know. An example of this problem would be if an animal number is supposed to be DRV-1M001 and we are told it should be DRV1M001 (without the dash). When we have received improper animal identification, our SEND files will have a compatibility problem when the data sets are combined, or harmonized with the in-life SEND package. We have encountered animal identification issues that were more timeconsuming to resolve since our pathology capture database was set up with incorrect animal identifiers.
Prospects and Promises
What has worked well at EPL is that the control terminology has not given us much trouble. Most of the issues we run into involve study-specific, nonstandard tissue names which we explain in the SDRG. Our processes are working well and since we generate mostly files in the MI data set, we can focus on that and turn studies around quickly. A nice by product of the SEND effort is that validation procedures have become more efficient. We know that at least one of our SEND data sets has been submitted successfully to FDA as part of a larger SEND package for a successful NDA.
Going forward, EPL will continue to cement our internal processes, perform cross-training and increase overall awareness of SEND, and solicit more feedback from clients on our data submissions. 
SEND and INHAND: Challenges and Prospects in Pharmaceutical Industries

Challenges
From the perspective of the pharmaceutical industry, developing standardized terminology for microscopic pathology is quite challenging. Anatomic pathology is primarily a descriptive science with many "shades of gray." The current requirements of the SEND model dictate that the diagnosis be segmented into defined fields. Pathologists may view this as restrictive and not compatible with how their company's data entry lexicon is organized. However, data collection systems can be interfaced with SEND extract software, such that the diagnosis can be mapped to the appropriate SEND fields. INHAND representatives work closely in a positive collaboration with the SEND Controlled Terminology committee to ensure that INHAND terms are mapped appropriately and new terms are reviewed and added, or modifications made, if needed, to existing INHAND and SEND terms.
Prospects and Promises
On the positive side, delivering standardized data will lead to efficiencies in regulatory submissions, providing one standard used by sponsors and vendors. When data are submitted in a standardized format, it can be searched within a study, across studies within a program, or across different programs. It will allow regulatory reviewers to more effectively review the submission and communicate any questions more specifically to the sponsor. Sponsors will also be developing tools to maintain internal data from SEND extracts. The collaboration between the INHAND GESC, FDA CDER, CDISC, and EVS represents a renewed endeavor to harmonize nonclinical data for regulatory submission, enhancing communication between pathologists, toxicologists, and regulatory scientists worldwide. 
SEND at CDER/FDA
Challenges
Actually, there are no identifiable disadvantages to data submission in SEND format as it pertains to its utilization by the pharmacology/toxicology reviewers. However, there are some challenges in having the pharmacology/toxicology reviewer become familiar with the SEND submissions and utilizing the visualization/analytical tools to view the submitted data. To mitigate these potential challenges, CDER/FDA has implemented several training courses for pharmacology/toxicology reviewers to get familiar with SEND and the visualization tools. In addition, pharmacology/toxicology reviewers from individual divisions are volunteering and providing their input in the designing of the visualization tool as well as beta testing the software as it is being developed with the ongoing feedback from the reviewers.
Prospects and Promises
The SEND is a standard format for sponsors to submit nonclinical study. It allows presentation of nonclinical data in a consistent and predictable manner. It facilitates automated analyses of data and the use of analytical and review tools. Currently, SEND data are accepted for single-dose toxicity studies, repeat-dose toxicity studies, and carcinogenicity studies. The SEND submissions contain the study report in a PDF format, a nonclinical study data reviewer's guide, a define file and data sets related to the studies noted above. After validation of the SEND submission by the Office of Computation Sciences, the reviewers at CDER have access to the SEND submission; however, they require a visualization tool to access and view the data. The visualization tool, which is a software that can be developed by any software company (not unique to FDA), allows the reviewer to create consistent tables and visualizations that facilitate communications within and across review teams. Currently, the tools allow reviewers to visualize representations of change from control, to "drill down" into summary data, and quickly locate all study endpoint data for individual animals. Therefore, the reviewers have more time to focus on science, spend less time digging out data for individual animal from line listings, and thus use more of their time to conduct a more thorough scientific review of the submission.
SEND-related Questions
Some of the most relevant SEND-related questions asked during panel discussion are listed below along with the answers:
Question: How are special stains mapped in the SENDcompliant lexicon? Reply: Special stains can be mapped to the MIMETHOD variable. Question: Since FDA pharm/tox reviewers will be using the SEND data set during their review and so rely on those data to draw conclusions, then: 1. Will the FDA consider the SEND data to be raw data? Reply: FDA does not consider SEND data as the raw data. 2. When FDA compliance auditors review a particular study at a test facility, will they also be reviewing the SEND data? Reply: This would be under the purview of the Office of Compliance; however, from a general point of view SEND data following submission is validated by the Office of Computational Science. Question: What is your procedure for mapping a new finding not already present in the SEND-compliant lexicon? What are the logistics of doing it? Is the pathologist able to add a new term, and if he/she does create one, who does the mapping and when? Does it happen in real time as each study's pathology is completed or not until a SEND file is created? . Tissue-specific terms from INHAND are included on the NONNEO codelist when it is important to use the exact term representing a spectrum of tissue changes (e.g., chronic progressive nephropathy). In the process of mapping terms from INHAND to SEND, some inconsistencies have been noted for the same term across several organ systems (e.g., thrombus vs. thrombosis). These will be harmonized using the new change control process and the most current INHAND terminology will be available on the goRENI website. The SEND list will continue to grow as INHAND publishes additional organ systems. Question: When does a pathologist know if a term is not SEND-compliant? If this happens after the study/pathology report is finalized, then an amendment is needed. What if the study pathologist is on vacation or this correction is not done in a timely manner? What can be done to satisfy/help the sponsor in these cases? Reply: Upon completion of the SEND extract, there should be a listing of those terms that are not SEND-compliant. An amendment would only be needed if the pathologist and study director determined it is important to adjust the term to something that is SEND-compliant. Otherwise, the original diagnoses should be submitted along with an explanation in the Study Reviewer's Guide defining the terminology that was used. Going forward, of course, it would be helpful to have the pathology terms in the data entry system map to SEND-compliant terms.
in ensuring that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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